Patents by Inventor Randolf Kerschbaumer

Randolf Kerschbaumer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
    Publication number: 20230365671
    Abstract: The invention refers to anti-oxMIF antibodies with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains and optionally increased effector functions due to further substitutions in the heavy chain constant regions, and their use in the treatment of oxMIF-related conditions.
    Type: Application
    Filed: October 1, 2021
    Publication date: November 16, 2023
    Inventors: Alexander SCHINAGL, Irina MIRKINA, Randolf KERSCHBAUMER, Robert Michael THIELE
  • ANTI-oxMIF/ANTI-CD3 BISPECIFIC ANTIBODY CONSTRUCTS
    Publication number: 20230045873
    Abstract: The invention refers to an anti-oxMIF/anti-CD3 antibody comprising at least one binding site specifically recognizing oxMIF and one binding site specifically recognizing CD3, which is an IgG wherein a scFv is fused to only one of the two heavy IgG chains, an IgG wherein one Fab arm is replaced by a bispecific-T-cell-engager (BiTE), or an IgG wherein both Fab arms are replaced by scFvs with different binding specificities, and its use in the treatment of hyperproliferative diseases, specifically in the treatment of cancer.
    Type: Application
    Filed: December 4, 2020
    Publication date: February 16, 2023
    Inventors: Alexander SCHINAGL, Michael Robert THIELE, Randolf KERSCHBAUMER
  • Anti-MIF immunohistochemistry
    Patent number: 11402388
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anti-oxMIF antibodies are used.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: August 2, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
  • ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
    Publication number: 20220002398
    Abstract: The invention refers to an anti-ox MIF/anti-CD3 antibody comprising at least one binding site specifically recognizing ox MIF and at least one binding site specifically recognizing CD3 and its use in the treatment of hyperproliferative diseases, specifically in the treatment of cancers.
    Type: Application
    Filed: June 7, 2019
    Publication date: January 6, 2022
    Inventors: Michael Robert THIELE, Alexander SCHINAGL, Randolf KERSCHBAUMER
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS
    Publication number: 20210187105
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
    Type: Application
    Filed: December 31, 2020
    Publication date: June 24, 2021
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • DETECTION OF CHO-MIF CONTAMINATIONS
    Publication number: 20200207840
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • Detection of CHO-MIF contaminations
    Patent number: 10626166
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: April 21, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • Anti-MIF immunohistochemistry
    Patent number: 10613100
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: April 7, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS
    Publication number: 20180280501
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
    Type: Application
    Filed: November 1, 2017
    Publication date: October 4, 2018
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • DETECTION OF CHO-MIF CONTAMINATIONS
    Publication number: 20180215807
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Application
    Filed: August 21, 2015
    Publication date: August 2, 2018
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • ANTI-MIF ANTIBODIES IN THE TREATMENT OF CANCERS CONTAINING MUTANT TP53 AND/OR MUTANT RAS
    Publication number: 20180155419
    Abstract: The present invention pertains to anti-MIF antibodies, preferably in combination with cancer therapeutics, i.e. chemotherapeutic agents, in the treatment of cancers containing mutant TP53 and/or mutant RAS.
    Type: Application
    Filed: May 18, 2016
    Publication date: June 7, 2018
    Inventors: Patrice Douillard, Randolf Kerschbaumer, Michael Thiele, Salim Yazji
  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20170065686
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: April 8, 2016
    Publication date: March 9, 2017
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND CHEMOTHERAPEUTICS
    Publication number: 20170049885
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with cancer therapeutics, i.e. chemotherapeutics, in the treatment of cancer.
    Type: Application
    Filed: June 6, 2016
    Publication date: February 23, 2017
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Hartmut Ehrlich
  • ANTI-MIF IMMUNOHISTOCHEMISTRY
    Publication number: 20160334414
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, and of anti-oxMIF antibodies in tissues. A detection method is provided which uses immunohistochemistry or immunofluorescence and wherein specific anti-oxMIF antibodies and specific idiotypic monoclonal rabbit antibodies are used.
    Type: Application
    Filed: January 2, 2015
    Publication date: November 17, 2016
    Inventors: Alexander Schinagl, Michael Thiele, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 9309506
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: April 12, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • ANTI-MIF ANTIBODY CELL MIGRATION ASSAY
    Publication number: 20150309012
    Abstract: The present invention pertains to a robust, precise and easy-to-use assay for potency of anti-MIF antibodies. In particular, the invention discloses an anti-MIF antibody-cell migration assay and respective method and kit.
    Type: Application
    Filed: December 5, 2013
    Publication date: October 29, 2015
    Inventors: Michael Thiele, Randolf Kerschbaumer
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS
    Publication number: 20150250873
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glycocorticoid receptive diseases.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 10, 2015
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • ANTI-MIF IMMUNOHISTOCHEMISTRY
    Publication number: 20150160235
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anfi-oxMIF antibodies are used.
    Type: Application
    Filed: July 9, 2013
    Publication date: June 11, 2015
    Inventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND CHEMOTHERAPEUTICS
    Publication number: 20150071942
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with therapeutics, i.e. chemotherapeutics, in the treatment of cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 12, 2015
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Hartmut Ehrlich
  • ANTI MIF ANTIBODIES
    Publication number: 20150023978
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Application
    Filed: January 17, 2014
    Publication date: January 22, 2015
    Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SA
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet